Access to AlloTx for AML: the value of the social phenotype
Related Posts
Cluzeau T, Borate U, McMahon C, Fenaux P, Heiblig M, Peterlin P, Ball B, Chantepie S, Eghtedar A, Kambhampati S, Solh M, Torregrosa-Diaz J, Braun[...]
Zheng D, Nold T, Ramakrishnan N, Kim K, Tomassetti S. Real-World Management of Chronic Myelogenous Leukemia in an Underserved Patient Cohort at a Los Angeles[...]
Itagi P, Schuster SL, Arora S, Persse TW, Waters JA, Yang M, Min A, Chandra P, Adil M, Galipeau PC, Rudoy D, Kreitman AS, Lin[...]